VISTA targeted nanobodies / Faeth Therapeutics - LARVOL DELTA

Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlights (GlobeNewswire) - "In August, Sensei announced it had selected SNS-101, a potent pH-dependent product candidate that selectively blocks the interaction of VISTA with its receptor, PSGL-1, in the low pH tumor microenvironment; VSIG4 (V-Set and Immunoglobulin Domain Containing 4)...Sensei plans to select a product candidate from this program in 2023; SNS-401-NG...Sensei intends to initiate IND-enabling studies for this product candidate in the second half of 2022."

Clinical • Pipeline update • Oncology • Solid Tumor

Sensei Biotherapeutics Reports First Quarter 2021 Results and Provides Business Update (GlobeNewswire) - "First Quarter and Recent Highlights: Strengthened Immuno-Oncology Advisory Board and Board of Directors - In May 2021, Sensei announced that it appointed Maura Gillison, M.D., Ph.D...to its Immuno-Oncology Advisory Board....Anticipated Pipeline Milestones and Events: IND-Enabling Studies on Track: Sensei announced it is on track to initiate IND-enabling studies for its SNS-VISTA program by year-end 2021."

Announcement • IND • Oncology